The available evidence is of insufficient quality, consistency, or statistical power to permit a conclusion regarding the presence or absence of an association in humans. This is true particularly when PB exposures occur in combination with other combat exposures.

REFERENCES

Abou-Donia MB, Wilmarth KR, Abdel-Rahman AA, Jensen KF, Oehme FW, Kurt TL. 1996a. Increased neurotoxicity following concurrent exposure to pyridostigmine bromide, DEET, and chlorpyrifos. Fundam Appl Toxicol 34(2):201–222.

Abou-Donia MB, Wilmarth KR, Jensen KF, Oehme FW, Kurt TL. 1996b. Neurotoxicity resulting from coexposure to pyridostigmine bromide, DEET, and permethrin: Implications of Gulf War chemical exposures. J Toxicol Environ Health 48(1):35–56.

Adkins S, Gan KN, Mody M, La Du BN. 1993. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: Glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet 52(3):598–608.

Adler M, Hinman D, Hudson CS. 1992. Role of muscle fasciculations in the generation of myopathies in mammalian skeletal muscle. Brain Res Bull 29(2):179–187.

Alhalel A, Ziv I, Versano D, Ruach M, Alkalay M, Almog S, Izraeli S, Glovinsky J. 1995. Ocular effects of hyoscine in double dose transdermal administration and its reversal by low dose pyridostigmine. Aviat Space Environ Med 66(11):1037–1040.

Almog S, Winkler E, Amitai Y, Dani S, Shefi M, Tirosh M, Shemer J. 1991. Acute pyridostigmine overdose: A report of nine cases. Isr J Med Sci 27(11–12):659–663.

Amos ML, Smith ME. 1998. The effect of pyridostigmine administration on the expression of pro-opiomelanocortin-derived peptides in motoneurones. Neurotoxicology 19(6):799–808.

Aquilonius SM, Eckernas SA, Hartvig P, Lindstrom B, Osterman PO. 1980. Pharmacokinetics and oral bioavailability of pyridostigmine in man. Eur J Clin Pharmacol 18(5):423–428.

Aquilonius SM, Eckernas SA, Hartvig P, Lindstrom B, Osterman PO, Stalberg E. 1983. Clinical pharmacology of pyridostigmine and neostigmine in patients with myasthenia gravis. J Neurol Neurosurg Psychiatry 46(10):929–935.

Arad M, Roth A, Zelinger J, Zivner Z, Rabinowitz B, Atsmon J. 1992a. Safety of pyridostigmine in hypertensive patients receiving beta blockers. Am J Cardiol 69(5):518–522.

Arad M, Varssano D, Moran D, Arnon R, Vazina A, Epstein Y. 1992b. Effects of heat– exercise stress, NBC clothing, and pyridostigmine treatment on psychomotor and subjective measures of performance. Mil Med 157(4):210–214.

Arsura EL, Brunner NG, Namba T, Grob D. 1987. Adverse cardiovascular effects of anticholinesterase medications. Am J Med Sci 293(1):18–23.

Arvat E, Gianotti L, Di Vito L, Imbimbo BP, Lenaerts V, Deghenghi R, Camanni F, Ghigo E. 1995. Modulation of growth hormone-releasing activity of hexarelin in man. Neuroendocrinology 61(1):51–56.

Arvat E, Di Vito L, Gianotti L, Ramunni J, Boghen MF, Deghenghi R, Camanni F, Ghigo E. 1997a. Mechanisms underlying the negative growth hormone (GH) autofeedback on the GH-releasing effect of hexarelin in man. Metabolism 46(1):83–88.

Arvat E, Di Vito L, Ramunni J, Gianotti L, Giordano R, Deghenghi R, Camanni F, Ghigo E. 1997b. Low hexarelin dose and pyridostigmine have additive effect and potenti-



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement